Growth Hormone Releasing Hormone analogue (with DAC) that extends GH pulse duration for sustained, amplified growth hormone elevation.
CJC-1295 is a synthetic analogue of Growth Hormone Releasing Hormone (GHRH), the endogenous hypothalamic peptide that signals the anterior pituitary to produce and release growth hormone. The key innovation of CJC-1295 is the addition of a Drug Affinity Complex (DAC) — a lysine-linker modification that allows the peptide to bind to serum albumin in the bloodstream. This binding dramatically extends the half-life of CJC-1295 from approximately 7 minutes (native GHRH) to 6–8 days, enabling sustained GH pulse elevation from a single administration.
By mimicking the action of native GHRH at the pituitary, CJC-1295 amplifies the amplitude of each growth hormone pulse without disrupting the body's natural pulsatile release pattern. This is critical for maintaining healthy IGF-1 levels and avoiding the receptor desensitization that can occur with constant GH elevation. The extended half-life means patients require fewer injections while still achieving consistent GH optimization throughout the week.
CJC-1295 is most commonly prescribed in combination with Ipamorelin. While CJC-1295 acts on GHRH receptors to amplify pulse size, Ipamorelin acts on ghrelin receptors to increase pulse frequency. This dual-pathway approach produces a synergistic effect that is significantly more effective than either peptide alone for improving body composition, recovery, sleep quality, and skin/hair health.
Extends the duration and amplitude of each growth hormone pulse, producing sustained elevation in GH and IGF-1 levels for days after each administration.
Sustained GH elevation promotes fat oxidation and supports lean mass retention, helping optimize the ratio of muscle to body fat over time.
Elevated GH and IGF-1 support tissue repair, collagen synthesis, and reduced recovery time from training and physical stress.
Growth hormone plays a key role in collagen production and skin cell turnover. Many patients report improved skin elasticity, thickness, and hair quality.
Seeking sustained GH optimization to support training recovery, lean mass development, and competitive performance over time.
Wanting to counteract age-related GH decline to support skin quality, body composition, energy, and overall vitality.
Seeking improved deep-sleep architecture and overnight recovery through enhanced nocturnal GH pulsing.
CJC-1295 is included in several physician-designed protocol stacks:
CJC-1295 with DAC was developed by ConjuChem Biotechnologies and has undergone multiple Phase I and Phase II clinical trials. Studies have demonstrated dose-dependent increases in mean GH levels (up to 10-fold) and IGF-1 levels (up to 2-fold) that persisted for 6+ days following a single subcutaneous injection. The DAC technology represents a significant advancement in peptide pharmacokinetics, allowing for practical dosing schedules. The peptide's safety profile in clinical trials has been favorable, with injection-site reactions being the most commonly reported adverse event.
DAC stands for Drug Affinity Complex. It is a modification that allows CJC-1295 to bind to albumin in the blood, extending its half-life from minutes to days and enabling less frequent dosing.
They work through different receptor pathways (GHRH vs. ghrelin). CJC-1295 amplifies GH pulse amplitude; Ipamorelin increases frequency. Together, they produce a synergistic GH response greater than either alone.
Due to its extended half-life, CJC-1295 with DAC is typically administered 1–2 times per week via subcutaneous injection. Your physician will determine the appropriate schedule.
No. CJC-1295 works by amplifying your body's own GH release pattern, not by introducing exogenous growth hormone. The natural feedback mechanisms remain intact.
CJC-1295 is not currently FDA-approved. It is prescribed off-label by licensed physicians and compounded at 503a/503b pharmacies under applicable regulations.
Individual results may vary. This information is for educational purposes only. All peptide therapies require a physician evaluation and prescription.
A physician will evaluate whether CJC-1295 is right for your performance and body composition goals.
Check Your Eligibility →